Details of the Drug Combination

General Information of Drug Combination (ID: DCMPJLB)

Drug Combination Name

Asciminib Asciminib

Indication

Disease Entry	Status	REF
Chronic Myelogenous Leukemia	Phase 3	[1]

Component Drugs

Asciminib DM7EVUF

Small molecular drug

2D MOL

3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)

Indication(s) of Asciminib

Disease Entry	ICD 11	Status	REF
Chronic myeloid leukaemia	2A20	Approved	[2]

Asciminib Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Fusion protein Bcr-Abl (Bcr-Abl)	TTS7G69	BCR_HUMAN-ABL1_HUMAN	Inhibitor	[3]
------------------------------------------------------------------------------------

Indication(s) of Asciminib

Disease Entry	ICD 11	Status	REF
Chronic myeloid leukaemia	2A20	Approved	[2]

Asciminib Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Fusion protein Bcr-Abl (Bcr-Abl)	TTS7G69	BCR_HUMAN-ABL1_HUMAN	Inhibitor	[3]
------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT04948333) Asciminib Treatment Optimization in ?3rd Line CML-CP.
2	FDA Approved Drug Products from FDA Official Website. 2022. Application Number: 215358.
3	Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure. N Engl J Med. 2019 Dec 12;381(24):2315-2326.